Cell and gene therapies involve extracting cells, protein or genetic material (DNA) from the patient and altering them to provide a highly personalised therapy, which is re-injected into the patient. Cell and gene therapies have the potential to address complex diseases, such as motor neurone disease, and many rare disorders for which there are no effective treatments. According to market research study published by Gen Consulting Company, the global cell and gene therapy related products market is expected to reach approximately USD 10,461 million, representing a CAGR of 7.7% during the forecast period 2022-2028.

The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into global cell and gene therapy related products market. It offers an exclusive insight into various details such as market size, key trends, competitive landscape, growth rate and market segments. This study also provides an analysis of the impact of the COVID-19 crisis on the cell and gene therapy related products industry.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the product, disease, and region. The global market for cell and gene therapy related products can be segmented by product: bioreactors, cell separation, cytokine release syndrome testing, GMP antibodies, GMP proteins, immunoassays, leukapheresis, media, vectors. Cell and gene therapy related products market is further segmented by disease: blood disorders, cancer, others. The cancer segment is estimated to account for the largest share of the global cell and gene therapy related products market. Based on region, the cell and gene therapy related products market is segmented into: Asia Pacific, Europe, North America, Rest of the World (RoW). Europe held the largest share of the global cell and gene therapy related products market in 2021 and is anticipated to hold its share during the forecast period.

By product:
– bioreactors
– cell separation
– cytokine release syndrome testing
– GMP antibodies
– GMP proteins
– immunoassays
– leukapheresis
– media
– vectors

By disease:
– blood disorders
– cancer
– others

By region:
– Asia Pacific
– Europe
– North America
– Rest of the World (RoW)

The report has also analysed the competitive landscape of the global cell and gene therapy related products market with some of the key players being Abcam plc, Adverum Biotechnologies, Inc., Athersys, Inc., AVROBIO Inc, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Cellgenix Gmbh, Cytiva (Global Life Sciences Solutions USA LLC), Luminex Corporation, Merck KGaA, Mesoblast Limited, Miltenyi Biotec GmbH, Quanterix Corp., Sartorius AG, STEMCELL Technologies Inc., Thermo Fisher Scientific Inc., among others.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Historical & Forecast Period
This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year.

Scope of the Report
– To analyze and forecast the market size of the global cell and gene therapy related products market.
– To classify and forecast the global cell and gene therapy related products market based on product, disease, region.
– To identify drivers and challenges for the global cell and gene therapy related products market.
– To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global cell and gene therapy related products market.
– To identify and analyze the profile of leading players operating in the global cell and gene therapy related products market.

Why Choose This Report
– Gain a reliable outlook of the global cell and gene therapy related products market forecasts from 2022 to 2028 across scenarios.
– Identify growth segments for investment.
– Stay ahead of competitors through company profiles and market data.
– The market estimate for ease of analysis across scenarios in Excel format.
– Strategy consulting and research support for three months.
– Print authentication provided for the single-user license.